A novel risk score model based on four angiogenesis long non-coding RNAs for prognosis evaluation of pancreatic adenocarcinoma

Abstract

Background: Long non-coding RNAs (lncRNAs) have been reported to play significant roles in tumour angiogenesis which prominently facilitates pancreatic adenocarcinoma (PAAD) progression. Methods: The clinical PAAD data were obtained from TCGA database and clinical specimens of 122 PAAD patients. The Molecular Signatures Database v4.0 was used to identify angiogenesis-related long non-coding RNAs (ARLNRs). Survival-related ARLNRs (sARLNRs) were further validated by univariate and multivariate COX regression analyses. The expressions of CASC8, AC015660.1, Z97832.2 and PAN3-AS1 in PAAD cell lines and tissues were examined by qPCR. The correlations between sARLNRs (CASC8 and AC015660.1) and clinicopathological characteristics of the 122 PAAD patients were analyzed by the chi-square test and Fisher's exact probability method.Results: 590 lncRNAs were identified as ARLNRs, of which four sARLNRs were further used to establish an angiogenesis-related risk score model (ARRS), by which patients in the low-risk group have better survival probabilities than those in the high-risk group. The expression levels of CASC8 and AC015660.1 were significantly higher in PAAD cell lines and tumor tissues especially in patients with advanced grades and T-stages, while Z97832.2 and PAN3-AS1 were inverse. In addition, the higher expression of CASC8 and AC015660.1 prominently associated with the larger tumour size, and the more advanced grade and T-stage. However, the relevance between the sARLNRs (CASC8 and AC015660.1) expression and lymph node metastasis status was not significant. Conclusions: In the study, we illuminate the clinical significance, angiogenesis relevance and prognosis-predictive value of four sARLNRs for PAAD. The results build a bridge between sARLNRs and tumour vascularization, and also establish a reliable and accurate risk scoring model for PAAD antiangiogenic strategy.

The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma

“…[ 42 ] AC015660.1 also can be used as an angiogenic factor-related lncRNAs to evaluate the prognosis of pancreatic cancer. [ 43 ] In our study, AC015660.1, as a genomic instability-associated lncRNA, was involved in predicting the prognosis of pancreatic cancer, indicating that AC015660.1 may be a potential target for PAAD treatment. LYPLAL1-AS1 rejuvenates human adipose-derived mesenchymal stem cells and can be used as a therapeutic target to resist hADSC senescence.…”

Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell

“…LINC01091 can coordinate the microRNA-128-3p/ELF4/CDX2 axis and thus promote gastric cancer growth and metastasis by way of exosomes on one hand ( 60 ) and can act as hub lncRNA in DNA methylation-related prognostic signatures of prostate cancer ( 61 ). AC015660.1 is involved in the angiogenesis of PAAD ( 62 ) and inflammatory correlation of gastric cancer ( 63 ) as hub lncRNA of prognostic signatures. In contrast, AC007292.2 has no previous relevant studies.…”